Table of Content

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Type of Dosage Forms
3.3. Overview of Oral Solid Dosage Forms
3.3.1. Components of Oral Solid Dosage Forms
3.3.2. Classification of Oral Solid Dosage Forms
3.3.3. Manufacturing of Oral Solid Dosage Forms
3.3.4. Emerging Trends in Oral Solid Dosage Manufacturing
3.4. Overview of Oral Solid Contract Manufacturing
3.4.1. Services Offered by CMOs and CDMOs for Oral Solid Manufacturing
3.4.2. Key Considerations While Selecting a CDMO or CMO Partner
3.4.3. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations
3.5. Future Perspectives

4. ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS (CMOs): MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Oral Solid Dosage CMOs: List of Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Ownership
4.2.5. Analysis by Type of Service(s) Offered
4.2.6. Analysis by Type of Finished Dosage Form
4.2.7. Analysis by Type of Tablet(S) Manufactured
4.2.8. Analysis by Type of Capsule(s) Manufactured
4.2.9. Analysis by Type of Multi-particulate(s) Manufactured
4.2.10. Analysis by Type of Primary Packaging Offered
4.2.11. Analysis by Scale of Operation
4.2.12. Analysis by High Potency Drug Manufacturing
4.2.13. Analysis by Availability of Continuous Manufacturing
4.2.14. Analysis by Regulatory Certifications / Accreditations

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers in North America
5.4.1. Peer Group I: Companies in the US
5.4.2. Peer Group II: Companies in Canada
5.5. Company Competitiveness Analysis: Oral Solid Dosage Contract Manufacturers based in Europe
5.5.1. Peer Group III: Companies in EU5
5.5.2. Peer Group IV: Other European Countries
5.6. Company Competitiveness Analysis: Oral Solid Contract Manufacturers based in Asia-Pacific and Rest of the World
5.6.1. Peer Group V: Companies in India
5.6.2. Peer Group VI: Companies in China
5.6.3. Peer Group VII: Companies in Japan
5.6.4. Peer Group VIII: Companies in Other Asia-Pacific and rest of the World
5.7. Company Competitiveness Analysis of Oral Solid Dosage Contract Manufacturers: Competitiveness Score of Top Service Providers

6. REGIONAL CAPABILITY ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Overall Landscape of Oral Solid Dosage Contract Manufacturing Facilities
6.4. Oral Solid Dosage Contract Manufacturers in North America
6.5. Oral Solid Dosage Contract Manufacturers in Europe
6.6. Oral Solid Dosage Contract Manufacturers in Asia-Pacific and Rest of the World

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Oral Solid Dosage Contract Manufacturing Service Providers: North America
7.2.1. Alcami
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.2.1. Manufacturing Capabilities and Facilities
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Cambrex
7.2.2.1. Company Overview
7.2.2.2. Service Portfolio
7.2.2.2.1. Manufacturing Capabilities and Facilities
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Catalent
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.3.1. Manufacturing Capabilities and Facilities
7.2.3.4. Recent Developments and Future Outlook
7.3. Oral Solid Dosage Contract Manufacturing Service Providers: Europe
7.3.1. Aenova
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Service Portfolio
7.3.1.3.1. Manufacturing Capabilities and Facilities
7.3.1.4. Recent Developments and Future Outlook
7.3.2. Almac
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Service Portfolio
7.3.2.3.1. Manufacturing Capabilities and Facilities
7.3.2.4. Recent Developments and Future Outlook
7.3.3. Lonza
7.3.3.1. Company Overview
7.3.3.2. Financial Information
7.3.3.3. Service Portfolio
7.3.3.3.1. Manufacturing Capabilities and Facilities
7.3.3.4. Recent Developments and Future Outlook
7.4. Oral Solid Dosage Contract Manufacturing Service Providers: Asia-Pacific and Rest of the World
7.4.1. Hetero Drugs
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.2.1. Manufacturing Capabilities and Facilities
7.4.1.3. Recent Developments and Future Outlook
7.4.2. Ind-Swift Laboratories
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Service Portfolio
7.4.2.3.1. Manufacturing Capabilities and Facilities
7.4.2.4. Recent Developments and Future Outlook
7.4.3. Rubicon Research
7.4.3.1. Company Overview
7.4.3.2. Service Portfolio
7.4.3.2.1. Manufacturing Capabilities and Facilities
7.4.3.3. Recent Developments and Future Outlook

8. MAKE VERSUS BUY DECISION FRAMEWORK
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Oral Solid Dosage Manufacturers: Make versus Buy Decision Making
8.3.1. Scenario 1
8.3.2. Scenario 2
8.3.3. Scenario 3
8.3.4. Scenario 4
8.4. Concluding Remarks

9. RECENT EXPANSIONS
9.1. Chapter Overview
9.2. Oral Solid Dosage Contract Manufacturers: Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Year and Type of Expansion
9.2.4. Analysis by Type of Oral Solid Dosage Form(s) Involved
9.2.5. Analysis by Type of Expansion and Oral Solid Dosage Form(s) Involved
9.2.6. Analysis by Type of Service(s) Offered
9.2.7. Analysis by Scales of Operation
9.2.8. Analysis by Location of Facility
9.2.9. Expansions Focused on Highly Potent Compounds

10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.2.1. Oral Solid Dosage Contract Manufacturing: Annual Global Capacity (Number of Finished Dosages)
10.2.1.1. Analysis by Company Size
10.2.1.2. Analysis by Scale of Operation
10.2.1.3. Analysis by Type of Finished Dosage Form
10.2.1.4. Analysis by Location of Manufacturing Facility
10.2.1.5. Analysis by Company Size and Type of Finished Dosage Form
10.2.1.6. Analysis by Company Size and Location of Manufacturing Facility
10.2.1.7. Analysis by Scale of Operation and Location of Manufacturing Facility
10.2.2. Oral Solid Dosage Contract Manufacturing: Annual Global Capacity (Amount of API)
10.2.2.1. Analysis by Company Size
10.2.2.2. Analysis by Scale of Operation
10.2.2.3. Analysis by Type of Finished Dosage Form
10.2.2.4. Analysis by Company Size and Type of Finished Dosage Form
10.2.2.5. Analysis by Company Size and Location of Manufacturing Facility
10.2.2.6. Analysis by Scale of Operation and Location of Manufacturing Facility
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Annual Demand for Oral Solid Doses, 2023-2035
11.4. Annual Outsourced Commercial Demand for Oral Solid Doses, 2023-2035
11.4.1. Annual Outsourced Commercial Demand for Oral Solid Doses: Distribution by Geography, 2023 and 2035
11.4.1.1. Annual Outsourced Commercial Demand for Oral Solid Doses in North America, 2023-2035
11.4.1.2. Annual Outsourced Commercial Demand for Oral Solid Doses in Europe, 2023-2035
11.4.1.3. Annual Outsourced Commercial Demand for Oral Solid Doses in Asia-Pacific and Rest of the World, 2023-2035
11.4.2. Annual Outsourced Commercial Demand for Oral Solid Doses: Distribution by Therapeutic Area, 2023 and 2035
11.4.2.1. Annual Outsourced Commercial Demand for Oral Solid Doses for Oncological Disorders, 2023-2035
11.4.2.2. Annual Outsourced Commercial Demand for Oral Solid Doses for Infectious Diseases, 2023-2035
11.4.2.3. Annual Outsourced Commercial Demand for Oral Solid Doses for Cardiovascular Disorders, 2023-2035
11.4.2.4. Annual Outsourced Commercial Demand for Oral Solid Doses for Metabolic Disorders, 2023-2035
11.4.2.5. Annual Outsourced Commercial Demand for Oral Solid Doses for Neurological Disorders, 2023-2035
11.4.2.6. Annual Outsourced Commercial Demand for Oral Solid Doses for Genetic Disorders, 2023-2035
11.4.2.7. Annual Outsourced Commercial Demand for Oral Solid Doses for Respiratory Disorders, 2023-2035
11.4.2.8. Annual Outsourced Commercial Demand for Oral Solid Doses for Immunological Disorders, 2023-2035
11.4.2.9. Annual Outsourced Commercial Demand for Oral Solid Doses for Other Disorders, 2023-2035
11.5. Annual Outsourced Clinical Demand for Oral Solid Doses, 2023-2035
11.5.1. Annual Outsourced Clinical Demand for Oral Solid Doses: Distribution by Trial Phase, 2023-2035
11.5.1.1. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase I Trials, 2023-2035
11.5.1.2. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase II Trials, 2023-2035
11.5.1.3. Annual Outsourced Clinical Demand for Oral Solid Doses in Phase III Trials, 2023-2035
11.6. Correlation between Annual Demand and Capacity

12. TOTAL COST OF OWNERSHIP FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURING ORGANIZATIONS
12.1. Chapter Overview
12.2. Key Parameters
12.3. Assumptions and Methodology
12.4. Sample Dataset for the Estimation of Total Cost of Ownership
12.5. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations, Y0-Y20
12.6. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by CapEx and OpEx, Y0 and Y20
12.6.1. Total Cost of Ownership for Oral Solid Contract Manufacturing Organizations: Analysis by CapEx, Y0
12.6.2. Total Cost of Ownership for Oral Solid Dosage Contract Manufacturing Organizations: Analysis by OpEx, Y0-Y20
12.7. Concluding Remarks

13. REGULATORY LANDSCAPE FOR ORAL SOLID DOSAGE CONTRACT MANUFACTURERS
13.1. Chapter Overview
13.2. Regulatory Guidelines in North America
13.2.1. The US Scenario
13.2.1. Canadian Scenario
13.3. Regulatory Guidelines in Europe
13.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
13.4.1. Chinese Scenario
13.4.2. Indian Scenario
13.4.3. Japanese Scenario
13.4.4. South Korean Scenario
13.4.5. Australian Scenario
13.4.6. Brazilian Scenario
13.5. Oral Solid Dosage CMOs: Information on Approval From Various Regulatory Authorities
13.6. Bubble Analysis: Regional Regulatory Summary

14. CASE STUDY ON TASTE MASKING SERVICES AND TECHNOLOGIES: MARKET LANDSCAPE
14.1. Chapter Overview
14.2. Taste Masking and Taste Assessment Service Providers
14.2.1. Analysis by Year of Establishment
14.2.2. Analysis by Company Size
14.2.3. Analysis by Location of Headquarters
14.2.4. Analysis by Year of Establishment and Location of Headquarters
14.3. Taste Masking and Taste Assessment Services: Overall Market Landscape
14.3.1. Analysis by Service(s) Offered
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Other Service(s) Offered
14.3.4. Analysis by Type of Formulation(s)
14.3.5. Analysis by End Users
14.3.6. Analysis by Techniques Used for Taste Masking
14.3.7. Analysis by Branch of Healthcare
14.3.8. Analysis by Regional Capability

15. CASE STUDY ON BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES: MARKET LANDSCAPE
15.1. Chapter Overview
15.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
15.2.1. Analysis by Year of Establishment
15.2.2. Analysis by Company Size
15.2.3. Analysis by Location of Headquarters
15.2.4. Analysis by Bioavailability Enhancement Principle
15.2.5. Analysis by Bioavailability Enhancement Approach
15.2.5.1. Analysis by Solid Dispersion Approaches
15.2.5.2. Analysis by Size Reduction Approaches
15.2.5.3. Analysis by Lipid-Based Approaches
15.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
15.2.6. Analysis by Dosage Form
15.2.7. Analysis by Route of Administration

16. MARKET FORECAST
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.2.1. Overall Oral Solid Dosage Contract Manufacturing Market, 2023-2035
16.2.2. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Finished Dosage Form
16.2.2.1. Tablet Manufacturing Market, 2023-2035
16.2.2.2. Capsule Manufacturing Market, 2023-2035
16.2.2.3. Powder Manufacturing Market, 2023-2035
16.2.2.4. Multi-particulates Manufacturing Market, 2023-2035
16.2.2.5. Other Finished Dosage Forms Manufacturing Market, 2023-2035
16.2.3. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Type of Packaging
16.2.3.1. Oral Solid Dosage Contract Manufacturing Market for Bottles, 2023-2035
16.2.3.2. Oral Solid Dosage Contract Manufacturing Market for Blisters, 2023-2035
16.2.3.3. Oral Solid Dosage Contract Manufacturing Market for Inhalers, 2023-2035
16.2.3.4. Oral Solid Dosage Contract Manufacturing Market for Sachets, 2023-2035
16.2.3.5. Oral Solid Dosage Contract Manufacturing Market for Strips, 2023-2035
16.2.3.6. Oral Solid Dosage Contract Manufacturing Market for Stick Packs, 2023-2035
16.2.4. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Scale of Operation
16.2.4.1. Oral Solid Dosage Contract Manufacturing Market for Pre-Commercial Scale, 2023-2035
16.2.4.2. Oral Solid Dosage Contract Manufacturing Market for Commercial Scale, 2023-2035
16.2.5. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Company Size
16.2.5.1. Oral Solid Dosage Contract Manufacturing Market for Small Companies, 2023-2035
16.2.5.2. Oral Solid Dosage Contract Manufacturing Market for Mid-sized Companies, 2023-2035
16.2.5.3. Oral Solid Dosage Contract Manufacturing Market for Large Companies, 2023-2035
16.2.5.4. Oral Solid Dosage Contract Manufacturing Market for Very Large Companies, 2023-2035
16.2.6. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Therapeutic Area
16.2.6.1. Oral Solid Dosage Contract Manufacturing Market for Oncological Disorders, 2023-2035
16.2.6.2. Oral Solid Dosage Contract Manufacturing Market for Infectious Diseases, 2023-2035
16.2.6.3. Oral Solid Dosage Contract Manufacturing Market for Cardiovascular Disorders, 2023-2035
16.2.6.4. Oral Solid Dosage Contract Manufacturing Market for Metabolic Disorders, 2023-2035
16.2.6.5. Oral Solid Dosage Contract Manufacturing Market for Neurological Disorders, 2023-2035
16.2.6.6. Oral Solid Dosage Contract Manufacturing Market for Genetic Disorders, 2023-2035
16.2.6.7. Oral Solid Dosage Contract Manufacturing Market for Respiratory Disorders, 2023-2035
16.2.6.8. Oral Solid Dosage Contract Manufacturing Market for Immunological Disorders, 2023-2035
16.2.6.9. Oral Solid Dosage Contract Manufacturing Market for Other Disorders, 2023-2035
16.2.7. Oral Solid Dosage Contract Manufacturing Market, 2023-2035: Distribution by Geographical Regions
16.2.7.1. Oral Solid Dosage Contract Manufacturing Market in North America, 2023-2035
16.2.7.2. Oral Solid Dosage Contract Manufacturing Market in Europe, 2023-2035
16.2.7.3. Oral Solid Dosage Contract Manufacturing Market in Asia-Pacific, 2023-2035
16.2.7.4. Oral Solid Dosage Contract Manufacturing Market in Latin America, 2023-2035
16.2.7.5. Oral Solid Dosage Contract Manufacturing Market in Middle East and North Africa, 2023-2035
17. EXECUTIVE INSIGHTS
18. CONCLUDING REMARKS
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS